Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection

Hepatitis B virus (HBV) infects 240 million people worldwide. Current therapy profoundly suppresses HBV replication but requires long-term maintenance therapy. Therefore, there is still a medical need for an efficient HBV cure. HBV enters host cells by binding via the preS1 domain of the viral L pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemori, Toshitada, Sugimoto-Ishige, Akiko, Nishitsuji, Hironori, Futamura, Yushi, Harada, Michishige, Kimura-Someya, Tomomi, Matsumoto, Takehisa, Honma, Teruki, Tanaka, Miho, Yaguchi, Masami, Isono, Kyoichi, Koseki, Haruhiko, Osada, Hiroyuki, Miki, Daiki, Saito, Takashi, Tanaka, Takashi, Fukami, Takehiro, Goto, Toshio, Shirouzu, Mikako, Shimotohno, Kunitada, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906425/
https://www.ncbi.nlm.nih.gov/pubmed/34985994
http://dx.doi.org/10.1128/jvi.01686-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906425/
https://www.ncbi.nlm.nih.gov/pubmed/34985994
http://dx.doi.org/10.1128/jvi.01686-21

Ejemplares similares